Jeremy Weaver
Physician Assistant · van Buren, ARNPI 1790014447
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$655
- Novo Nordisk$525
- Lilly USA, LLC$490
- Amgen$449
- GSK$310
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,54098%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $1,138 |
| AstraZeneca(2 entities) | 33 | $655 |
| Novo Nordisk | 31 | $525 |
| Lilly USA, LLC | 34 | $490 |
| Amgen | 29 | $449 |
| GSK | 25 | $310 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $239 |
| Pfizer | 15 | $238 |
| Boehringer Ingelheim | 13 | $189 |
| Exact Sciences | 8 | $147 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Sumitomo Pharma America, Inc. | 8 | $133 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $130 |
| Astellas Pharma US Inc | 2 | $98 |
| Biohaven Pharmaceuticals, Inc. | 7 | $97 |
| Antares Pharma, Inc. | 5 | $96 |
| Johnson & Johnson | 6 | $90 |
| Bayer | 5 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Boston Scientific | 1 | $23 |
| Merck | 1 | $23 |
| Tonix Medicines, Inc. | 1 | $21 |
| Corium, LLC | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$5,625 in reported general payments places this provider in the 90th percentile of 451 physician assistant providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 54 | $51,048 |
| OzempicSemaglutide | 42 | $44,107 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $43,086 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $40,171 |
| MounjaroTirzepatide | 35 | $37,708 |
| JardianceEmpagliflozin | 41 | $36,542 |
| JanuviaSitagliptin Phosphate | 33 | $29,317 |
| XareltoRivaroxaban | 32 | $27,180 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $15,824 |
| QuliptaAtogepant | 14 | $15,097 |
| LinzessLinaclotide | 12 | $12,741 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $10,088 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 400 | $9,186 |
| MyrbetriqMirabegron | 12 | $8,125 |
| FarxigaDapagliflozin Propanediol | 12 | $6,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $655 | $52,64881 claims |
| PfizerEliquis | $238 | $51,04854 claims |
| Novo NordiskOzempic | $525 | $44,10742 claims |
| GSKTrelegy Ellipta | $310 | $43,08650 claims |
| Lilly USA, LLCMounjaro | $490 | $37,70835 claims |
| Boehringer IngelheimJardiance | $189 | $36,54241 claims |
| MerckJanuvia | $23 | $29,31733 claims |
| AbbVieQulipta, Linzess | $1,138 | $27,83826 claims |
| Johnson & JohnsonXarelto | $90 | $27,18032 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $8,12512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 451 physician assistant providers in Arkansas.
Other physician assistant in van Buren
- Honey SchaumburgFort Smith$397K
- Adrienne EasterlingRogers$366K
- Katherine RossLittle Rock$44K
- Benton LoggainsFort Smith$39K
- Monte DouglasJacksonville$38K
- Anna StilinovicFayetteville$32K
- Timothy BookerLittle Rock$13K
- Callie PooleJonesboro$12K
- Bryce BassFort Smith$11K
- Kayla MouryFort Smith$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.